<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00718250</url>
  </required_header>
  <id_info>
    <org_study_id>O5CC14</org_study_id>
    <secondary_id>EudraCT 2005-000806-29</secondary_id>
    <secondary_id>GTAC GTAC098</secondary_id>
    <nct_id>NCT00718250</nct_id>
  </id_info>
  <brief_title>Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2</brief_title>
  <acronym>RFUSIN2-AML1</acronym>
  <official_title>A Phase I Study of Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) Expressing B7.1 (CD80) and IL-2 for the Potential Enhancement of Graft Versus Leukaemia(GvL) Effect in Poor Prognosis AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leukemia Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Elimination of Leukaemia Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College Hospital NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of an 'AML Cell Vaccine'
      in patients with poor prognosis acute myeloid leukaemia (AML).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2008</start_date>
  <completion_date type="Anticipated">February 2012</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and safety of the 'AML Cell Vaccine'</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>relapse, leukaemia free survival and overall survival</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML Cell Vaccine alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Donor leukocytes alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML cell vaccine and Donor Leukocyte Infusion (1x107/kg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AML cell vaccine and Donor Leukocyte Infusion (1x108/kg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RFUSIN2-AML1</intervention_name>
    <description>AML cell vaccine alone. x4 doses 3 weeks apart</description>
    <arm_group_label>cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Donor leukocyte infusion (DLI)</intervention_name>
    <description>1 dose 1x107/kg</description>
    <arm_group_label>cohort 2</arm_group_label>
    <other_name>RFUSIN2-AML1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RFUSIN2-AML1 and donor leukocyte infusion</intervention_name>
    <description>AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose</description>
    <arm_group_label>cohort 3</arm_group_label>
    <other_name>RFUSIN2-AML1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RFUSIN2-AML1 and donor leukocyte infusion</intervention_name>
    <description>AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose</description>
    <arm_group_label>cohort 4</arm_group_label>
    <other_name>RFUSIN2-AML1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AML defined according to the WHO classification

          -  Age ≥ 18 years

          -  New presentation or relapsed AML

          -  Patients must be able to give written informed consent

          -  Failure to enter complete morphological remission (&gt;5% bone marrow AML cells) or
             persistence of cytogenetic abnormality following intensive combination chemotherapy At
             day+100 post-transplant

          -  HIV negative

          -  No GvHD

          -  No continuing use of immunosuppressive drugs

          -  Absence of active systemic fungal or viral infection including HTLV-1, hepatitis B or
             C.

          -  Adequate renal and liver function confirmed by: creatinine clearance &gt;30mls/min;
             bilirubin &lt;3.0 x upper limit of normal; AST &lt;3.0 x upper limit of normal; prothrombin
             time &lt;2.0 x upper limit of normal.

        Performance status of 1 or less by ECOG criteria or &gt;80% by the Karnovsky score

          -  Patient must provide written informed consent and be willing to comply for the
             duration of the study.

          -  Life expectancy &gt;36 weeks

          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test within 10 - 14 days and again within 24 hours of starting the study. In addition,
             sexually active WCBP must agree continued abstinence from heterosexual intercourse or
             to use adequate contraceptive methods starting 4 weeks prior to the initiation of
             therapy (see appendix G for pregnancy testing and birth control guidelines while on
             study). WCBP must agree to have pregnancy tests every 3 weeks while on study drug
             (every 14 days for women with irregular cycles) and 4 weeks after the last dose of
             study drug. Men must also agree to use a condom if their partner is of child bearing
             potential, even if they have had a successful vasectomy.

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Patients not fit for intensive chemotherapy

          -  Complete morphological and cytogenetic remission following intensive combination
             chemotherapy

          -  Absence of HLA compatible donor

          -  HIV positive

          -  Evidence of graft versus host disease at day+100 post transplant

          -  Evidence of relapse of leukaemia (≥5% bone marrow blasts)

          -  Concurrent use of other forms of anti-leukaemic therapy

          -  Other malignancy with the exception of carcinoma in situ.

          -  Significant history of heart disease (unstable angina, myocardial within the past six
             months, congestive cardiac failure requiring daily treatment)

          -  Evidence of active lung disease determined by chest x-ray and absence of chronic lung
             disease (FEV1&lt;60% predicted, Vital capacity &lt;60%, Tlco&lt;50%)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ghulam J Mufti</last_name>
    <role>Principal Investigator</role>
    <affiliation>King's College London, London, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ghulam J Mufti</last_name>
    <phone>+44 2032999000</phone>
    <phone_ext>3080</phone_ext>
    <email>ghulam.mufti@kcl.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Ingram</last_name>
    <phone>+44 2032999000</phone>
    <phone_ext>4642</phone_ext>
    <email>wendy.ingram@kch.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 6, 2008</study_first_submitted>
  <study_first_submitted_qc>July 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2008</study_first_posted>
  <last_update_submitted>July 16, 2008</last_update_submitted>
  <last_update_submitted_qc>July 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr Lorraine Catt, Research and Development Manager</name_title>
    <organization>King's College Hospital NHS Foundation Trust, London, United Kingdom</organization>
  </responsible_party>
  <keyword>Acute myeloid leukaemia</keyword>
  <keyword>Cancer vaccines</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

